Biote Corp. ( (BTMD) ) has released its Q1 earnings. Here is a breakdown of the information Biote Corp. presented to its investors.
Biote Corp., a prominent player in the preventive healthcare sector, specializes in personalized hormone optimization and therapeutic wellness solutions. The company recently reported strong financial results for the first quarter of 2025, driven by increased gross margins from vertical integration and growth in its dietary supplements business.
Biote Corp. achieved a revenue of $49.0 million, marking a 4.7% increase from the previous year. The company reported a net income of $15.8 million, a significant turnaround from a net loss of $5.7 million in the prior year. The gross profit margin improved to 74.3%, attributed to the vertical integration of their 503B manufacturing facility. Despite a decrease in procedure revenue, dietary supplements revenue saw a substantial increase of 25.5%.
The company announced a strategic organizational restructuring aimed at sustainable growth and long-term value creation. This includes realigning their commercial organization, enhancing sales efficiency, and maximizing value from existing providers. The restructuring is expected to incur a charge related to severance costs in the upcoming quarter.
Looking ahead, Biote Corp. maintains its financial outlook for 2025, with expectations of revenue growth driven by increased dietary supplements and procedure revenues. The company remains focused on optimizing its sales and marketing strategies to strengthen its commercial organization and continue its mission in the therapeutic wellness market.